Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Am J Transplant ; 13(4): 861-874, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23432943

ABSTRACT

Acute vascular rejection (AVR) is characterized by immune-mediated vascular injury and heightened endothelial cell (EC) apoptosis. We reported previously that apoptotic ECs release a bioactive C-terminal fragment of perlecan referred to as LG3. Here, we tested the possibility that LG3 behaves as a neoantigen, fuelling the production of anti-LG3 antibodies of potential importance in regulating allograft vascular injury. We performed a case-control study in which we compared anti-LG3 IgG titers in kidney transplant recipients with AVR (n=15) versus those with acute tubulo-interstitial rejection (ATIR) (n=15) or stable graft function (n=30). Patients who experienced AVR had elevated anti-LG3 titers pre and posttransplantation compared to subjects with ATIR or stable graft function (p<0.05 for both mediators). Elevated pretransplant anti-LG3 titers (OR: 4.62, 95% CI: 1.08-19.72) and pretransplant donor-specific antibodies (DSA) (OR 4.79, 95% CI: 1.03-22.19) were both independently associated with AVR. To address the functional role of anti-LG3 antibodies in AVR, we turned to passive transfer of anti-LG3 antibodies in an animal model of vascular rejection based on orthotopic aortic transplantation between fully MHC-mismatched mice. Neointima formation, C4d deposition and allograft inflammation were significantly increased in recipients of an ischemic aortic allograft passively transferred with anti-LG3 antibodies. Collectively, these data identify anti-LG3 antibodies as novel accelerators of immune-mediated vascular injury and obliterative remodeling.


Subject(s)
Graft Rejection/immunology , Heparan Sulfate Proteoglycans/immunology , Immunoglobulin G/blood , Vascular Diseases/immunology , Adult , Animals , Antigens/immunology , Aorta/pathology , Apoptosis , Case-Control Studies , Endothelial Cells/pathology , Female , Graft Rejection/blood , Humans , Immunization, Passive , Immunoglobulin G/immunology , Inflammation/pathology , Kidney/blood supply , Kidney/pathology , Kidney Transplantation/adverse effects , Kidney Transplantation/methods , Male , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Middle Aged , Recombinant Proteins/immunology , Retrospective Studies , Vascular Diseases/blood
2.
Gene ; 198(1-2): 399-406, 1997 Oct 01.
Article in English | MEDLINE | ID: mdl-9370308

ABSTRACT

The segmented double-stranded RNA genome of Choristoneura fumiferana cytoplasmic polyhedrosis virus (CfCPV) was extracted, polyadenylated, reverse-transcribed into cDNA and cloned. The cDNA clones that hybridized to the smallest genomic segment (segment 10) were identified, and its nucleotide sequence was determined. Genome segment 10 of CfCPV was found to be 1171 nucleotides in length with a single open reading frame in one strand capable of coding a predicted protein of 258 residues (Mr of 29,795), consistent with an apparent Mr of 30.5 kDa determined by SDS-PAGE of purified polyhedrin. Comparison of the nucleotide and amino acid sequences of the polyhedrin gene of CfCPV with those of other CPVs and with several nuclear polyhedrosis viruses revealed no particular homology. Analysis of the hydrophilic profiles and predicted secondary structures of Bombyx mori (BmCPV), Euxoa scandens (EsCPV) and CfCPV indicated the presence of seven similar regions located at the amino terminus of the polyhedrin polypeptide of the three viruses. The expression of the cloned CfCPV polyhedrin gene in Escherichia coli demonstrated that this polyhedrin has the property of self-assembly, since the production of crystal-like occlusion with a well-defined crystalline lattice structure was observed.


Subject(s)
Moths/virology , Reoviridae/genetics , Viral Proteins/genetics , Animals , Base Sequence , Cloning, Molecular , Crystallization , Escherichia coli , Molecular Sequence Data , Molecular Weight , Occlusion Body Matrix Proteins , Protein Structure, Secondary , Solubility , Viral Proteins/chemistry , Viral Structural Proteins
SELECTION OF CITATIONS
SEARCH DETAIL
...